Reports Q4 revenue $212.528M vs $146.377M last year. “Apellis (APLS) made significant strides in 2024, highlighted by the continued growth of SYFOVRE and the unprecedented phase 3 results for EMPAVELI in C3G and IC-MPGN,” said Cedric Francois, M.D., Ph.D., chief executive officer at Apellis. “With two potential blockbuster products, a promising pipeline to fuel long-term growth, and a strong financial foundation, we are well positioned for continued growth in 2025 and beyond.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Options Volatility and Implied Earnings Moves Today, February 28, 2025
- Apellis Pharmaceuticals (APLS) Q4 Earnings Cheat Sheet
- Apellis announces EMA validation of Aspaveli indication extension application
- Apellis Pharmaceuticals: Buy Rating Affirmed Amid FDA Approval and Strategic Market Positioning
- Hold Rating for Apellis Pharmaceuticals Amid Competitive Challenges and Reimbursement Concerns